Theranostics 2022; 12(9):4374-4385. doi:10.7150/thno.72966 This issue


Recent advances in understanding the role of HES6 in cancers

Imène Krossa1,2,‡, Thomas Strub1,2,‡, Arnaud Martel1,3,‡, Sacha Nahon-Esteve1,3, Sandra Lassalle1,4, Paul Hofman1,4, Stéphanie Baillif1,3, Robert Ballotti1,2,#, Corine Bertolotto1,2,✉

1. Université Côte d'Azur, France
2. Inserm, Biology and Pathologies of melanocytes, team1, Equipe labellisée Ligue 2020 and Equipe labellisée ARC 2019, Centre Méditerranéen de Médecine Moléculaire, Nice, France
3. Centre Hospitalier Universitaire de Nice, Department of Ophthalmology, Nice, France
4. Laboratoire de Pathologie clinique et expérimentale, biobanque BB-0033-00025, and IRCAN team 4, FHU OncoAge, Nice, France
‡: These authors equally contributed
#: These authors jointly supervised this work

This is an open access article distributed under the terms of the Creative Commons Attribution License ( See for full terms and conditions.
Krossa I, Strub T, Martel A, Nahon-Esteve S, Lassalle S, Hofman P, Baillif S, Ballotti R, Bertolotto C. Recent advances in understanding the role of HES6 in cancers. Theranostics 2022; 12(9):4374-4385. doi:10.7150/thno.72966. Available from

File import instruction


Graphic abstract

The NOTCH signaling system regulates a variety of cellular processes during embryonic development and homeostasis maintenance in different tissues and contexts. Hence, dysregulation of NOTCH signaling is associated with a plethora of human cancers, and there have been multiple efforts to target key components of this pathway. In this review, we briefly highlight the latest research advances in understanding HES6, a poorly studied component of the NOTCH pathway. We summarize the role of HES6 in cancers with a focus on uveal melanoma. Finally, we discuss the ongoing efforts to target the NOTCH-HES6 axis in cancers.

Keywords: HES6, cancers, uveal melanoma, NOTCH, signaling